New investment in Zetta Genomics
We Venture Capital lead the seed extension round of 4.3m EUR in Zetta Genomics.
The new investment enables Zetta to increase its go to market and scale-up activities. During the next years, Zetta will focus on converting its strong pipeline into customers resulting in growth to its annual recurring revenue. The investment is the first scale-up round after years of successful product development.
We are deeply impressed with Xetabase, the platform developed by Zetta. The solution unlocks the data potential of genomics through enabling real-time scalable use & tertiary analysis of large complex datasets. The platform is continuously updated with the latest scientific breakthroughs keeping all patient samples active. We look forward to supporting Zetta on their future journey.
Louise Warme, Head of We Venture Capital
Zetta is a British company that has developed a genomic informatics platform, providing tertiary analysis of NGS testing. The technology enables analysis at scale with the ability to host hundreds of thousands of NGS on the platform, which are updated real time for new clinically relevant information.
Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With our second seed funding round now finalised, we are scaling and innovating our technologies and enhancing customer focus.
Ignacio Medina, Zetta Genomics CEO
We Venture Capital invest alongside Nina Capital, Cambridge Enterprise Nova Capital and other institutional investors.
About We Venture Capital
We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.
We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.
About Zetta Genomics
Zetta Genomics unleashes the power of precision medicine to improve health outcomes for millions of patients around the world.
Founded in 2017, Zetta Genomics is a fast-scaling genomic data technology company headquartered in Cambridge, UK, with offices in Valencia, Spain. A spin-out from the University of Cambridge and Genomics England, Zetta Genomics concentrates genomic, big data and start-up expertise to deliver data management fit for the precision medicine era.
The company’s XetaBase genomic data management platform simplifies tertiary genomic data analysis – aggregating, indexing and enriching secondary data at scale and speed – to accelerate discovery, diagnosis and the delivery of genomic medicine.
For more information on Zetta, please contact zetta@milkandhoneypr.com or visit www.zettagenomics.com.